A Prospective, Open-label, Exploratory Interventional Trial of Preoperative Semaglutide Prior to Radical Prostatectomy for Intermediate-risk Localized Prostate Cancer

Registration

Registration

NCT07727473

Study type

INTERVENTIONAL

Phase

EARLY_PHASE1

Masking

NONE

Status

NOT_YET_RECRUITING

Enrollment

20

Start

2026-07

Primary completion

2028-05

Lead sponsor

Banner Health

Conditions

Prostate Cancer

Interventions

DRUG:Semaglutide 2.4 mg

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen [Baseline (pre-treatment biopsy) through radical prostatectomy, assessed up to 6 months]
• Change in Ki-67 proliferative index between baseline biopsy and radical prostatectomy specimen [Baseline through radical prostatectomy, assessed up to 6 months]
• Change in Gleason score from biopsy to prostatectomy specimen [Baseline biopsy through radical prostatectomy specimen collection, assessed up to 6 months]
• Change in Decipher genomic score in prostate tumor tissue [Baseline biopsy through radical prostatectomy specimen collection, assessed up to 6 months]